1. Home
  2. HTT vs LYEL Comparison

HTT vs LYEL Comparison

Compare HTT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo High Templar Tech Limited American depositary shares each representing one Class A ordinary share

HTT

High Templar Tech Limited American depositary shares each representing one Class A ordinary share

N/A

Current Price

$2.92

Market Cap

464.3M

Sector

Finance

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$12.70

Market Cap

401.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTT
LYEL
Founded
2014
2018
Country
China
United States
Employees
101
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
464.3M
401.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HTT
LYEL
Price
$2.92
$12.70
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
275.5K
90.6K
Earning Date
05-29-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
$4.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.88
$8.49
52 Week High
$3.91
$45.00

Technical Indicators

Market Signals
Indicator
HTT
LYEL
Relative Strength Index (RSI) 66.82 29.46
Support Level $2.63 $12.15
Resistance Level $2.99 $13.62
Average True Range (ATR) 0.08 1.32
MACD 0.03 -0.33
Stochastic Oscillator 75.26 17.78

Price Performance

Historical Comparison
HTT
LYEL

About HTT High Templar Tech Limited American depositary shares each representing one Class A ordinary share

High Templar Tech Ltd is an enabler of financial technology. High Templar is focusing on exploring business opportunities globally to satisfy clients' demand by leveraging its technology know-how and financial service capabilities. The company focus empowering financial institutions with its technological capabilities, helping them improve marketing and operational efficiency and efficiently connect their diverse financial products with online traffic.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: